Related Experiment Video
Updated: Feb 8, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein
Nicolas Bery1, Abimael Cruz-Migoni1,2, Carole Jr Bataille3
1MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Abstract:
The RAS family of proteins is amongst the most highly mutated in human cancers and has so far eluded drug therapy. Currently, much effort is being made to discover mutant RAS inhibitors and in vitro screening for RAS-binding drugs must be followed by cell-based assays. Here, we have developed a robust set of bioluminescence resonance energy transfer (BRET)-based RAS biosensors that enable monitoring of RAS-effector interaction inhibition in living cells. These include KRAS, HRAS and NRAS and a variety of different mutations that mirror those found in human cancers with the major RAS effectors such as CRAF, PI3K and RALGDS. We highlighted the utility of these RAS biosensors by showing a RAS-binding compound is a potent pan-RAS-effector interactions inhibitor in cells. The RAS biosensors represent a useful tool to investigate and characterize the potency of anti-RAS inhibitors in cells and more generally any RAS protein-protein interaction (PPI) in cells.
Insights
Researchers developed novel bioluminescence resonance energy transfer (BRET)-based RAS biosensors to monitor RAS-effector interactions in living cells, aiding the discovery of new cancer drugs targeting RAS mutations.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- RAS proteins are frequently mutated in human cancers, presenting a significant challenge for drug development.
- Current drug discovery for RAS mutations requires effective cell-based assays to validate in vitro findings.
Purpose of the Study:
- To develop and validate novel RAS biosensors for monitoring RAS-effector interactions in living cells.
- To provide a tool for assessing the efficacy of potential anti-RAS therapies.
Main Methods:
- Development of bioluminescence resonance energy transfer (BRET)-based biosensors for KRAS, HRAS, and NRAS.
- Incorporation of cancer-relevant RAS mutations and key RAS effectors (CRAF, PI3K, RALGDS).
- Utilized biosensors to monitor RAS-effector interaction inhibition in cellular assays.
Main Results:
- Demonstrated the utility of BRET-based RAS biosensors for real-time monitoring of RAS-effector interactions.
- Showcased a RAS-binding compound as a potent inhibitor of pan-RAS-effector interactions in cells.
- Validated the biosensors' capability to characterize anti-RAS inhibitors.
Conclusions:
- BRET-based RAS biosensors are a robust tool for investigating RAS protein-protein interactions (PPIs) in living cells.
- These biosensors facilitate the characterization of anti-RAS inhibitor potency and drug discovery efforts.
- The developed biosensors can be broadly applied to study various RAS-mediated cellular processes.
More Related Videos
06:44Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
10:20Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
Related Concept Videos
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
G-protein Coupled Receptors
Protein-protein Interfaces
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...